Hepatic Manifestations and Response to Treatment in Deficiency of Adenosine Deaminase 2
Liver International · 2026-06 · 46 (6)
DOI: 10.1111/liv.70660 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 04.05.2026. Verfasst von Mohammed Rifat Shaik und 17 weiteren Autor:innen. Beteiligte Einrichtung: Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Adenosine Deaminase, Splenomegaly, Hepatomegaly, Intercellular Signaling Peptides and Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background and Aims Deficiency of adenosine deaminase 2 (DADA2) is caused by mutations in the ADA2 gene and results in an auto‐inflammatory state. Hepatosplenomegaly, with or without abnormalities in liver enzymes, has been reported in DADA2. Anti‐tumour necrosis factor (anti‐TNF) therapy is the standard of care for the prevention of recurrent ischemic strokes and reduction of inflammatory burden. However, little is known about the extent of hepatic involvement and the utility of non‐invasive tools for identifying liver disease and monitoring treatment response.
Methods
Retrospective analysis was performed on a prospective cohort of 70 patients with DADA2. Patients underwent baseline and annual laboratory testing, abdominal imaging and transient elastography. Hepatomegaly and splenomegaly were assessed on imaging, with splenomegaly defined using the spleen‐to‐height (SH) ratio. Liver biopsy and esophagogastroduodenoscopy were performed when indicated.
Results
At baseline, elevated ALT was uncommon (29%). Hepatomegaly and splenomegaly were present in 36% and 58%, respectively. Liver biopsies were performed in 12 patients, 8 of whom showed porto‐sinusoidal vascular disease (PSVD). Over a median follow‐up of 4.5 years, 40% demonstrated persistently elevated ALT levels. Clinically evident portal hypertension was present in 14%, and decompensation events, such as ascites and variceal bleeding, occurred in 5%. Anti‐TNF therapy resulted in resolution of splenomegaly in 28% and a reduction in mean SH ratio across the entire cohort. Patients who underwent haematopoietic cell transplantation (HCT) appeared to be at risk for complications such as hepatic graft versus host disease and veno‐occlusive disease.
Conclusions
DADA2 vasculopathy appears to affect intrahepatic portal veins and result in PSVD. SH ratio shows significant promise in identifying liver involvement and monitoring treatment response. The improvement in SH suggests that PSVD may be reversible with treatment in this setting. Hepatic evaluation at baseline is encouraged for all patients, and pre‐HCT liver biopsy should be considered, as there can be clinically silent liver disease that could potentially cause transplant‐related complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
- Department of Internal Medicine, SSM Health/Saint Louis University School of Medicine, St. Louis, Missouri, USA.
- National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Radiology and Imaging Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
- Center for Immuno-Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
ORCID-Profile: Mohammed Rifat Shaik, David E Kleiner
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Shaik, M. R., Alao, H., Shaik, N. A., Kapuria, D., Gopalakrishna, H., Han, M. A. T., Takyar, V., Hoffmann, P., Stone, D., Wilson, L., Videgar-Laird, R., Redd, B., Kleiner, D. E., Koh, C., Kastner, D. L., Dimitrova, D., Ombrello, A. K., & Heller, T. (2026). Hepatic Manifestations and Response to Treatment in Deficiency of Adenosine Deaminase 2. Liver International, 46(6). https://doi.org/10.1111/liv.70660
Vancouver
Shaik MR, Alao H, Shaik NA, Kapuria D, Gopalakrishna H, Han MAT, et al. Hepatic Manifestations and Response to Treatment in Deficiency of Adenosine Deaminase 2. Liver International. 2026;46(6). doi:10.1111/liv.70660
BibTeX
@article{Shaik2026,
author = {Shaik, Mohammed Rifat and Alao, Hawwa and Shaik, Nishat Anjum and Kapuria, Devika and Gopalakrishna, Harish and Han, Ma Ai Thanda and Takyar, Varun and Hoffmann, Patrycja and Stone, Deborah and Wilson, Lorena and Videgar-Laird, Ryan and Redd, Bernadette and Kleiner, David E and Koh, Christopher and Kastner, Daniel L and Dimitrova, Dimana and Ombrello, Amanda K and Heller, Theo},
title = {Hepatic Manifestations and Response to Treatment in Deficiency of Adenosine Deaminase 2},
journal = {Liver International},
year = {2026},
volume = {46},
number = {6},
doi = {10.1111/liv.70660}
}
EUVIMED